Skip to main content
Micro-Tech (Nanjing) Co.,Ltd logo

Micro-Tech (Nanjing) Co.,Ltd — Investor Relations & Filings

Ticker · 688029 ISIN · CNE100003MG1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 662 across all filing types
Latest filing 2026-05-21 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688029

About Micro-Tech (Nanjing) Co.,Ltd

https://www.micro-tech.com.cn/

Micro-Tech (Nanjing) Co., Ltd. specializes in the research, development, and manufacturing of minimally invasive medical devices. The company focuses on providing advanced solutions for gastroenterology, respiratory medicine, and orthopedics. Its product portfolio includes a wide range of endoscopic diagnostic and therapeutic tools such as biopsy forceps, disposable hemoclips, biliary and esophageal stents, and specialized instruments for Endoscopic Mucosal Resection (EMR) and Endoscopic Submucosal Dissection (ESD). Micro-Tech emphasizes innovation and quality, maintaining international certifications to serve a global healthcare market. By integrating precision engineering with clinical needs, the company aims to improve patient outcomes and procedural efficiency for medical professionals worldwide.

Recent filings

Filing Released Lang Actions
南微医学科技股份有限公司关于2025年度暨2026年第一季度中英双语业绩说明会召开时间调整的公告
Regulatory Filings Classification · 90% confidence The document is a stock‐exchange announcement notifying investors of a change in timing for a bilingual ‘业绩说明会’ (performance explanation meeting). It contains no substantive financial results, presentation slides, or detailed analysis – only logistics and procedural details. It is not the investor presentation itself, nor any formal report release, but a regulatory notice of meeting schedule. As such it falls under the general regulatory announcements (RNS) category.
2026-05-21 Chinese
南微医学科技股份有限公司关于召开2025年度暨2026年第一季度中英双语业绩说明会的公告
Investor Presentation Classification · 65% confidence The document is an announcement by the company’s board regarding the scheduling and logistics of a bilingual performance explanation meeting (业绩说明会) covering the 2025 annual results and the 2026 first quarter. It does not contain any financial statements or analysis itself, nor is it a formal earnings release of results; rather, it invites investors to a presentation/webcast. This corresponds to an investor presentation event. Therefore, the document is classified as an Investor Presentation (IP).
2026-05-20 Chinese
江苏新高的律师事务所关于南微医学科技股份有限公司2025年年度股东会的见证法律意见书
Regulatory Filings Classification · 85% confidence The document is a legal opinion letter issued by a law firm regarding the legality and procedures of the company’s 2025 Annual General Meeting. It does not itself constitute an AGM presentation, minutes, financial report, proxy statement, or any of the specialized filing types. It is not related to litigation or regulatory enforcement either. Therefore, under the classification scheme it falls into the fallback category “Regulatory Filings” (RNS).
2026-05-19 Chinese
南微医学科技股份有限公司2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement of the 2025 Annual General Meeting resolutions, detailing shareholder attendance and the voting results on multiple proposals. It does not contain actual financial statements or constitute a report itself, but rather declares official voting outcomes at a shareholders’ meeting. This matches the “Declaration of Voting Results & Voting Rights Announcements” category.
2026-05-19 Chinese
南微医学科技股份有限公司2025年年度股东会会议资料
AGM Information Classification · 95% confidence The document is clearly titled “2025年年度股东会会议资料” and contains detailed materials for the company’s 2025 Annual General Meeting, including meeting notices, agenda, proposals, board reports, financial reports, remuneration schemes, and other attachments. It is not merely an announcement or summary but the full set of AGM presentation materials. This matches the definition of AGM Information (AGM-R).
2026-05-13 Chinese
南微医学科技股份有限公司2025年度“提质增效重回报”专项行动方案评估报告暨2026年度“提质增效重回报”专项行动方案
Management Reports Classification · 95% confidence The document is titled as an "Evaluation Report" and "Action Plan Report" for the years 2025 and 2026, issued by 南微医学科技股份有限公司 (Nanwei Medical Technology Co., Ltd.). It contains detailed narrative on company operational performance, strategic initiatives, innovation and R&D progress, global expansion, shareholder returns including dividends and share repurchase, ESG efforts, and governance improvements. The content is comprehensive and forward-looking, covering multiple aspects of company management and performance, typical of a management or operational report rather than a pure financial statement. There is no indication that this is a full annual report (10-K) or interim report (IR) with detailed financial statements. It is also not a simple announcement or certification. The document focuses on management's explanation of business trends, operational results, strategic outlook, and governance, which aligns with the definition of a Management Report (MDA). The length (6325 characters) and depth of content support this classification with high confidence.
2026-04-27 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.